Telesis Bio Appoints William J. Kullback Chief Financial Officer
29 août 2023 16h05 HE
|
Telesis Bio
SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial...
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
03 août 2023 17h00 HE
|
Telesis Bio
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter...
Telesis Bio Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
Telesis Bio
-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and...
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
09 mars 2023 16h30 HE
|
Telesis Bio
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08 sept. 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 17h11 HE
|
Translate Bio, Inc.
-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
03 août 2021 01h00 HE
|
Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07 juil. 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
22 juin 2021 01h00 HE
|
Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09 juin 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...